Table 3

Differences in changes in outcome measures over 24 months according to levels of SU between subgroups stratified by final dose of febuxostat

Outcome measure	Reduction in SU concentration at 24 months (mg/dL)	Group difference*	95% CI	Achieved SU concentration at 24 months (mg/dL)	Group difference*	95% CI
Mean CCA-IMT, mm	‒5.0	0.015	‒0.055 to 0.084	3.0	0.009	‒0.046 to 0.064
	‒4.0	‒0.006	‒0.042 to 0.029	4.0	‒0.025	‒0.057 to 0.006
	‒3.0	‒0.019	‒0.054 to 0.015	5.0	‒0.038	‒0.074 to ‒0.003
	‒2.0	‒0.014	‒0.057 to 0.028	6.0	‒0.019	‒0.066 to 0.029
	‒1.0	0.000	‒0.082 to 0.083	7.0	0.012	‒0.076 to 0.100
Log-scaled hs-CRP	‒5.0	‒0.426	‒1.258 to 0.406	3.0	0.126	‒0.479 to 0.731
	‒4.0	‒0.043	‒0.465 to 0.380	4.0	0.082	‒0.280 to 0.444
	‒3.0	0.183	‒0.222 to 0.587	5.0	0.001	‒0.406 to 0.409
	‒2.0	0.047	‒0.458 to 0.552	6.0	‒0.131	‒0.654 to 0.392
	‒1.0	‒0.277	‒1.261 to 0.707	7.0	‒0.281	‒1.222 to 0.660

*Group differences were calculated as the subgroup treated with high-dose febuxostat (≥30 mg daily) minus that with low-dose febuxostat (<30 mg daily).
CCA-IMT, common carotid artery intima–media thickness; hs-CRP, high-sensitivity C reactive protein; SU, serum urate.